Evidence map›Paper›PMID 26846650›Full record

ReviewTargeted oncology2016

Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?

Alessandra Modena, Francesco Massari, Chiara Ciccarese, Matteo Brunelli, Matteo Santoni, Rodolfo Montironi, Guido Martignoni, Giampaolo Tortora

Abstract readReview
PubMed Publisher
In one paragraph

Review in Targeted oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Alessandra ModenaMedical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), University of Verona, Piazzale L.A. Scuro 10, 37134, Verona, Italy.
Francesco MassariMedical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), University of Verona, Piazzale L.A. Scuro 10, 37134, Verona, Italy. fmassari79@gmail.com.
Chiara CiccareseMedical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), University of Verona, Piazzale L.A. Scuro 10, 37134, Verona, Italy.
Matteo BrunelliDepartment of Pathology and Diagnostic, Azienda Ospedaliera Universitaria Integrata (AOUI), University of Verona, Verona, Italy.
Matteo SantoniMedical Oncology, Azienda Ospedaliera Universitaria (AOU) Ospedali Riuniti, Polytechnic University of the Marche Region, Ancona, Italy.
Rodolfo MontironiSection of Pathological Anatomy, School of Medicine, Azienda Ospedaliera Universitaria (AOU) Ospedali Riuniti, Polytechnic University of the Marche Region, Ancona, Italy.
Guido MartignoniDepartment of Pathology and Diagnostic, Azienda Ospedaliera Universitaria Integrata (AOUI), University of Verona, Verona, Italy.
Giampaolo TortoraMedical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), University of Verona, Piazzale L.A. Scuro 10, 37134, Verona, Italy.
Azienda Ospedaliera Universitaria Integrata Verona · ITAzienda Ospedaliero Universitaria Ospedali Riuniti · ITUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite recent advances that have been made in the therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC), effective management of bone metastases remains a key goal not yet reached. The receptor tyrosine kinase MET and the vascular endothelial growth factor receptor (VEGFR) seem to play an important role in prostate cancer progression and pathological bone turnover, representing potential targets for improving clinical outcomes in mCRPC. Studies evaluating agents that target one or both these pathways have demonstrated modest activity but no improvement in overall survival. Nevertheless, this therapeutic strategy seems to still be a promising and engaging area of prostate cancer research and the interest in better understanding the MET/VEGFR axis and the mechanism of action of these inhibitors is growing. This review describes the rationale for targeting MET and VEGFR pathway in mCRPC and provides the clinical data available to date and an update on ongoing trials.

Indexed as

HumansMaleNeoplasm MetastasisProstatic Neoplasms, Castration-ResistantProto-Oncogene Proteins c-metVascular Endothelial Growth Factor AMET protein, humanProto-Oncogene Proteins c-metVascular Endothelial Growth Factor A

Identifiers

PMID26846650
OpenAlexW2266871100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.